Endothelin antagonism with bosentan: A review of potential applications

Journal of Molecular Medicine

Volumn 77, Issue 4, 1999, Pages 364-376

  Roux, Sébastien ^a   Breu, Volker ^a   Ertel, Sylvie I ^b   Clozel, Martine ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Sundgau Medical Writers   (France)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Bosentan; Endothelin; Endothelin receptors

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; DRUG EFFECT; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE RELAXATION; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; KINETICS; RATS; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TIME FACTORS;

EID: 0032968208     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050363     Document Type: Review

References (180)

1. Yanagisawa MH, Kurihara H, Kimura S, et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415
2. Inoue A, Yanagisawa M, Kimura S, et al (1989) The human endothelin family - three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863-2867
3. McMillen MA, Sumpio BE (1995) Endothelins: polyfunctional cytokines. J Am Coll Surg 180:621-637
4. Rubanyi GM, Polokoff MA (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 46:328-415
5. Goto K, Hama H, Kasuya Y (1996) Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 72:261-290
6. Nakayama K, Ishigai Y, Uchida H, Tanaka Y (1991) Potentiation by endothelin-1 of 5-hydroxytryptamine-induced contraction in coronary artery of the pig. Br J Pharmacol 104:978-986
7. MacLean MR, McGrath JC (1990) Effects of pre-contraction with endothelin-1 on alpha 2-adrenoceptor- and (endothelium-dependent) neuropeptide Y-mediated contractions in the isolated vascular bed of the rat tail. Br J Pharmacol 101:205-211
8. Lerman A, Edwards BS, Hallett JW, Heublin DM, Sandberg SM, Burnett JCJ (1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325:997-1001
9. Sakurai T, Yanagisawa M, Takuwa Y, et al (1990) Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 348:732-735
10. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S (1990) Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730-732
11. Ohlstein EH, Douglas SA (1993) Endothelin-1 modulates vascular smooth muscle structure and vasomotion: implications in cardiovascular pathology. Drug Dev Res 29:108-128
12. Ogawa Y, Nakao K, Arai H, et al (1991) Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 178:248-255
13. Warner TD, Mitchell JA, DeNucci G, Vane JR (1989) Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of rat and rabbit. J Cardiovasc Pharmacol 13:S85-S88
14. de Nucci G, Thomas R, D'Orleans-Juste D, et al (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 85:9797-9800
15. Jougasaki M, Schirger JA, Simari RD, Burnett JC, Jr (1998) Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension 32:917-922
16. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol 107:858-860
17. Simonson MS, Dunn MJ (1993) Endothelin peptides and the kidney. Annu Rev Physiol 55:249-265
18. B receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem Biophys Res Commun 196:209-215
19. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 89:1203-1208
20. Katwa LC, Guarda E, Weber KT (1993) Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 27:2125-2129
21. Wagner OF, Christ G, Wotja J, et al (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267:16066-16068
22. Lüscher TF, Seo B-G, Bühler FR (1993) Controversy on endothelin in hypertension: the potential role of endothelin in hypertension. Hypertension 21:752-757
23. Stewart DJ, Kubag G, Costello KB, Cernacek P (1991) Increased plasma endothelin-1 in early hours of acute myocardial infarction. J Am Coll Cardiol 18:38-43
24. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ (1992) Plasma endothelin in chronic heart failure. Circulation 85:1374-1379
25. Roux S, Löffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP (1995) The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37:78-85
26. Seo B, Lüscher TF (1995) ETA and ETB receptors mediate contraction to endothelin-1 in renal artery of aging SHR. Effects of FR139317 and bosentan. Hypertension 25:501-506
27. Dagassan PH, Breu V, Clozel M, et al (1996) Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 27:147-153
28. Clozel M, Gray GA (1995) Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 26 Suppl 3:S262-S264
29. Mickley EJ, Gray GA, Webb DJ (1997) Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries [published erratum appears in Br J Pharmacol 121:1239]. Br J Pharmacol 120:1376-1382
30. Clozel M, Breu V, Burri K, et al (1993) Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365:759-761
31. Neidhart W, Breu V, Bur D, et al (1996) The discovery of non-peptide endothelin receptor antagonists. Progression towards bosentan. Chimia 50:519-524
32. Fukami T, Nagase T, Fujita K, et al (1995) Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem 38:4309-4324
33. Ishikawa K, Ihara M, Noguchi K, et al (1994) Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 91:4892-4896
34. Aramori I, Nirei H, Shoubo M, et al (1993) Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol 43:127-131
35. B receptor antagonist (PD 145065) and related analogues. Med Chem Res 3:154-162
36. Cody WL, He JX, Reily MD, et al (1997) Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties. J Med Chem 40:2228-2240
37. Morishita Y, Chiba S, Tsukuda E, et al (1994) RES-701-1, a novel and selective endothelin type B receptor antagonist produced by Streptomyces sp. RE-701. I. Characterization of producing strain, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 47:269-275
38. Masuda Y, Sugo T, Kikuchi T, et al (1996) Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors. J Pharmacol Exp Ther 279:675-685
39. Opgenorth TJ, Adler AL, Calzadilla SV, et al (1996) Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276:473-481
40. B mixed antagonists. J Med Chem 40:3217-3227
41. Webb ML, Bird JE, Liu EC, et al (1995) BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J Pharmacol Exp Ther 272:1124-1134
42. Williams DL, Jr, Murphy KL, Nolan NA, et al (1996) Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist. Life Sci 58:1149-1157
43. Williams DL, Jr, Murphy KL, Nolan NA, et al (1995) Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J Pharmacol Exp Ther 275:1518-1526
44. Raschack M, Unger L, Riechers H, Klinge D (1995) Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 26 Suppl 3:S397-S299
45. Riechers H, Albrecht HP, Amberg W, et al (1996) Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem 39:2123-2128
46. Doherty AM, Patt WC, Edmunds JJ, et al (1995) Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J Med Chem 38:1259-123
47. B receptor. FEBS Lett 383:37-41
48. Clozel M, Breu V, Gray GA, et al (1994) Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 270:228-235
49. Roux S, Breu V, Giller T, et al (1997) Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283:1110-1118
50. Ohlstein EH, Nambi P, Douglas SA, et al (1994) SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 91:8052-8056
51. Ohlstein EH, Nambi P, Lago A, et al (1996) Nonpeptide endothelin receptor antagonists. VI. Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 276:609-615
52. Wu C, Chan MF, Stavros F, et al (1997) Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40:1690-1697
53. 3H]Bosentan binding to human coronary artery: functional correlates. J Cardiovasc Pharmacol 26:S376-S279
54. Tschudi MR, Lüscher TF (1994) Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun 204:685-690
55. Gater PR, Wasserman MA, Renzetti LM (1996) Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea. Eur J Pharmacol 304:123-128
56. Véniant M, Clozel JP, Hess P, Clozel M (1994) Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci 55:445-454
57. Phillips PA, Risvanis J, Aldred K, Burrell LM, Bartholomeusz B (1995) Differential effects of a novel non-peptide endothelin receptor antagonist (bosentan) in rat liver and vasculature. Clin Sci (Colch) 89:575-579
58. Wang QD, Li XS, Lundberg JM, Pernow J (1995) Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 29:805-812
59. B receptors in isolated porcine ophthalmic artery. Acta Physiol Scand 157:245-252
60. Gardiner SM, Kemp PA, March JE, Bennett T (1994) Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol 112:823-830
61. Lawrence E, Brain SD (1994) Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstriction in the rat skin. Eur J Pharmacol 260:103-106
62. Holm P, Liska J, Clozel M, Franco-Cereceda A (1996) The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 112:890-897
63. Teerlink JR, Carteaux JP, Sprecher U, Loffler BM, Clozel M, Clozel JP (1995) Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 268:H432-H440
64. Bartholomeusz B, Hardy KJ, Nelson AS, Phillips PA (1996) Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension 27:1341-1345
65. Weber C, Schmitt R, Birnboeck H, et al (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124-137
66. Li JS, Larivièire R, Schiffrin EL (1994) Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 24:183-188
67. Weitzberg E, Hemsen A, Rudehill A, Modin A, Wanecek M, Lundberg JM (1996) Bosentan-improved cardiopulmonary vascular performance and increased plasma levels of endothelin-1 in porcine endotoxin shock. Br J Pharmacol 118:617-626
68. Donckier J, Stoleru L, Hayashida W, et al (1995) Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 92:106-113
69. B receptors in rats. Biochem Biophys Res Commun 199:1461-1465
70. Hemsén A, Modin A, Wanecek M, Malmström RE, Weitzberg E (1996) Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig. Eur J Pharmacol 318:369-376
71. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M (1998) Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci 19:5-8
72. Takanashi M, Endoh M (1991) Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol 261:H611-H619
73. 2+ and contractility in single ventricular myocytes from the ferret and human. Eur J Pharmacol 214:293-296
74. Suzuki T, Hoshi H, Sasaki H, Mitsui Y (1991) Endothelin-1 stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. II. J Cardiovasc Pharmacol 17 Suppl 7:S182-S186
75. Hom GJ, Touhey B, Rubanyi GM (1992) Effects of intracoronary administration of endothelin in anesthetized dogs: comparison with Bay K 8644 and U 46619. J Cardiovasc Pharmacol 19:194-200
76. Salvati P, Chierchia S, Dho L, et al (1991) Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol 17:1007-1014
77. Harada M, Itoh H, Nakagawa O, et al (1997) Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 96:3737-3744
78. Hirata Y, Takagi Y, Fukuda Y, Marumo F (1989) Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225-228
79. Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M (1995) Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 269:H686-H695
80. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T (1989) A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J Biol Chem 264:7856-7861
81. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelly R (1992) Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85:504-509
82. 125I-labeled endothelin-1 binding in rat cardiac membranes. Am J Physiol 258:H829-H835
83. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M, Clozel JP (1994) Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 90:2510-2518
84. Wang QD, Hemsén A, Li XS, Lundberg JM, Uriuda Y, Pernow J (1995) Local overflow and enhanced tissue content od endothelin following myocardial ischemia and reperfusion in the pig: modulation by L-arginine. Cardiovasc Res 29:44-49
85. Tønnessen T, Naess PA, Kirkebøen KA, Offstad J, Ilebekk A, Christensen G (1993) Endothelin is released from the porcine coronary circulation after short-term ischemia. J Cardiovasc Pharmacol 22:S313-S316
86. Cavero PG, Miller WL, Heublein DM, Margulies KB, Burnett JCJ (1990) Endothelin in experimental congestive heart failure in the anesthetized dog. Am J Physiol 259:F312-F317
87. Velasco CE, Turner M, Inagami T, et al (1994) Reperfusion enhances the local release of endothelin after regional myocardial ischemia. Am Heart J 128:441-451
88. Kusumoto K, Awane Y, Fujiwara S, Watanabe T (1993) Role of endogenous endothelin in extension of rabbit myocardial infarction. J Cardiovasc Pharmacol 22:S339-S342
89. Pousset F, Isnard R, Lechat P, et al (1997) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18:254-258
90. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M (1995) Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 75:1282-1283
91. Janakidevi K, Fisher MA, Del Vecchio PJ, Tiruppathi C, Figge J, Malik AB (1992) Endothelin 1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle. Am J Physiol 263:C1295-C1301
92. Ito H, Hirata Y, Hiroe M, et al (1991) Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res 69:209-215
93. Miyauchi T, Sakai S, Ihara M, et al (1995) Increased endothelin-1 binding sites in the cardiac membranes in rats with chronic heart failure. J Cardiovasc Pharmacol 26 Suppl 3:S448-S451
94. Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better OS, Winaver J (1996) Bosentan improves renal regional blood flow in rats with experimental congestive heart failure. Eur J Pharmacol 310:193-196
95. Shimoyama H, Sabbah HN, Borzak S, et al (1996) Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 94:779-784
96. Mulder P, Richard V, Derumeaux G, et al (1997) Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96:1976-1982
97. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G (1997) Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96:3963-3973
98. Kiowski W, Sutsch G, Hunziker P, et al (1995) Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732-736
99. Sütsch G, Bertel O, Kiowski W (1997) Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 10:717-75
100. Sütsch G, Kiowski W, Yan X-W, et al (1998) Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98:2262-2268
101. Kiowski W, Sütsch G, Yan X-W, et al (1997) Neurohormonal effects of endothelin-1 receptor antagonist therapy in patients with chronic heart failure. Circulation 96:193
102. Heath D, Smith P, Gosney J, et al (1987) The pathology of the early and late stages of primary-pulmonary hypertension. Br Heart J 58:204-213
103. Giaid A, Yanagisawa M, Langleben D, et al (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732-1739
104. Ishikawa S, Miyauchi T, Ueno H, et al (1995) Influence of pulmonary blood pressure and flow on endothelin-1 production in humans. J Cardiovasc Pharmacol 26:429-433
105. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79:2122-2131
106. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S (1995) Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 268:H828-H835
107. Hess P, Clozel M, Clozel JP (1996) Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J Appl Physiol 81:1027-1032
108. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M (1994) Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 23:1427-1433
109. Schiffrin EL, Thibault G (1991) Plasma endothelin in human essential hypertension. Am J Hypertens 4:303-308
110. Kohno M, Yasunari K, Murakawa KI, et al (1990) Plasma immunoreactive endothelin in essential hypertension. Am J Med 88:614-618
111. Li JS, Schiffrin EL (1995) Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens 13:647-652
112. Li JS, Schiffrin EL (1995) Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 25:495-500
113. Li JS, Deng LY, Grove K, Deschepper CF, Schiffrin EL (1996) Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression. Hypertension 28:188-195
114. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T (1995) Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 115:1377-1381
115. Schiffrin EL, Larivière R, Li JS, Sventek P, Touyz RM (1995) Deoxycorticosterone acetate plus salt induce overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 25 (part 2):769-773
116. Verma S, Bhanot S, McNeill JH (1995) Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 269:H2017-H2021
117. Doucet J, Gonzalez W, Michel JB (1996) Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol 27:643-651
118. Otsuka A, Mikami H, Katahira K, Tsunetoshi T, Minamitani K, Ogihara T (1989) Changes in plasma renin activity and aldosterone concentration in response to endothelin injection in dogs. Acta Endocrinol (Copenh) 121:361-364
119. Karam H, Heudes D, Hess P, et al (1996) Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res 31:287-295
120. Li JS, Schurch W, Schiffrin EL (1996) Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 9:803-811
121. B endothelin receptor antagonist bosentan. Can J Physiol Pharmacol 73:390-398
122. Deng LY, Schiffrin EL (1992) Effects of endothelin-1 and vasopressin on small arteries of spontaneously hypertensive rats. Am J Hypertens 5:817-822
123. Karam H, Heudes D, Bruneval P, et al (1996) Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 28:379-385
124. Balakrishnan SM, Wang HD, Gopalakrishnan V, Wilson TW, McNeill JR (1996) Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 28:806-809
125. Casellas D, Bouriquet N, Herizi A (1997) Bosentan prevents preglomerular alterations during angiotensin II hypertension. Hypertension 30:1613-1620
126. Marsen TA, Schramek H, Dunn MJ (1994) Renal actions of endothelin: linking cellular signaling pathways to kidney disease. Kidney Int 45:336-344
127. Hocher B, Rohmeiss P, Zart R, et al (1995) Significance of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats: renal and hemodynamic effects of endothelin receptor antagonists. J Cardiovasc Pharmacol 26:S470-S472
128. Hocher B, Rohmeiss P, Zart R, et al (1996) Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats. Cardiovasc Res 31:499-510
129. Skov K, Fenger-Gron J, Mulvany MJ (1996) Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Hypertension 28:464-471
130. Bouriquet N, Dupont M, Herizi A, Mimran A, Casellas D (1996) Preglomerular sudanophilia in L-NAME hypertensive rats. Involvement of endothelin. Hypertension 27:382-391
131. Baumbach GL, Hajdu MA (1993) Mechanics and composition of cerebral arterioles in renal and spontaneously hypertensive rats. Hypertension 21:816-826
132. Chillon JM, Heistad DD, Baumbach GL (1996) Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension 27:794-798
133. Krum H, Viskoper RJ, Lacourcière Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784-790
134. Ergul S, Parish DC, Puett D, Ergul A (1996) Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension [published erratum appears in Hypertension 29:912]. Hypertension 28:652-655
135. Barone FC, Willette RN, Yue TL, Feurestein G (1995) Therapeutic effects of endothelin receptor antagonists in stroke. Neurol Res 17:259-264
136. Asano T, Ikegaki I, Suzuki S, Shibuya M (1989) Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 159:1345-1351
137. Shigeno T, Clozel M, Sakai S, Saito A, Goto K (1995) The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37:87-90
138. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K (1992) The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage. J Neurosurg 77:96-100
139. Ziv I, Heminger G, Djaldetti R, Achiron A, Melamed E, Sokolovski M (1992) Increased plasma endothelin-1 in acute ischaemic stroke. Stroke 23:1014-1016
140. Barone FC, Globus MY-T, Price WJ, et al (1994) Endothelin levels increase in rat focal and global ischaemia. J Cereb Blood Flow Metab 14:337-342
141. Finlay JM, Weir BKA, Kanamaru K, Espinosa F (1989) Arterial wall changes in cerebral vasospasm. Neurosurgery 25:736-746
142. Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H, Rapoport RM (1996) Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 84:503-507
143. Zimmermann M, Seifert V, Löffler BM, Stolke D, Stenzel W (1996) Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 38:115-120
144. Zimmermann (1997) Endothelin in cerebral vasospasm. J Neurosurg Sci 41:139-151
145. Zuccarello M, Kassell NF, Sasaki T, Fujiwara S, Nakagomi T, Lehman RM (1987) Barrier disruption in the major cerebral arteries after experimental subarachnoid hemorrhage in spontaneously hypertensive and normotensive rats. Neurosurgery 21:515-522
146. Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM (1995) Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J Neurosurg 83:503-509
147. Wallnöfer A, Grosset D, Öhman J, et al (1997) Effects of the endothelin antagonist bosentan in patients with elevated Doppler velocities after aneurysmal SAH. Proceedings of the 6th International Conference on Cerebral Vasospasm
148. Nord EP (1993) Renal actions of endothelin. Kidney Int 44:451-463
149. Lerman A, Hildebrand FL, Jr, Aarhus LL, Burnett JC Jr (1991) Endothelin has biological actions at pathophysiological concentrations. Circulation 83:1808-1814
150. Simonson MS, Jones JM, Dunn MJ (1992) Differential regulation of fos and jun gene expression and AP-1 cis-element activity by endothelin isopeptides. Possible implications for mitogenic signaling by endothelin. J Biol Chem 267:8643-8649
151. McMillen MA, Huribal M, Cunningham ME, Kumar R, Sumpio BE (1995) Endothelin-1 increases intracellular calcium in human monocytes and causes production of interleukin-6. Crit Care Med 23:34-40
152. Rabelink TJ, Kaasjager KAH, Stroes ESG, Koomans HA (1996) Endothelin in renal pathophysiology: from experimental to therapeutic application. Kidney Int 50:1827-1833
153. Karam H, Bruneval P, Clozel JP, Löffler BM, Bariéty J, Clozel M (1995) Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J Pharmacol Exp Ther 274:481-486
154. Kramer HJ, Schwarting K, Backer A, Meyer-Lehnert H (1997) Renal endothelin system in obstructive jaundice: its role in impaired renal function of bile-duct ligated rats. Clin Sci (Colch) 92:579-585
155. Oldroyd SD, Haylor JL, Morcos SK (1995) Bosentan, an orally active endothelin antagonist: effect on the renal response to contrast media. Radiology 196:661-665
156. Gómez-Garre D, Largo R, Liu XH, et al (1996) An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 50:962-972
157. Benigni A, Zola C, Corna D, et al (1996) Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 27:416-423
158. Clozel M, Qiu C, Osterwalder R, et al (in press) Effects of non-peptide endothelin receptor antagonists in rats with reduced renal mass. J Cardiovasc Pharmacol
159. Herrero I, Torras J, Riera M, et al (1997) Prevention of cold ischemia-reperfusion injury by an endothelin receptor antagonist in experimental renal transplantation. J Am Soc Nephrol:657A (abstract)
160. Brändli P, Loffler BM, Breu V, Osterwalder R, Maire JP, Clozel M (1996) Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64:315-322
161. Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16:157-168
162. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67:375-378
163. Li XS, Wang QD, Pernow J (1995) Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat. Eur J Pharmacol 283:161-168
164. Wang QD, Li XS, Pernow J (1995) The nonpeptide endothelin receptor antagonist bosentan enhances myocardial recovery and endothelial function during reperfusion of the ischemic rat heart. J Cardiovasc Pharmacol 26:S445-S447
165. Filep JG, Fournier A, Földes-Filep E (1995) Effects of the ETA/ETB receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat. Br J Pharmacol 116:1745-1750
166. Wenzel RR, Fleisch M, Shaw S, et al (1998) Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98:2235-2240
167. B receptors. Br J Pharmacol 115:227-236
168. Finsnes F, Skjonsberg OH, Tonnessen T, Naess O, Lyberg T, Christensen G (1997) Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 155:1404-1412
169. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K (1995) Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology 21:1138-1143
170. Asbert M, Gines A, Gines P, et al (1993) Circulating levels of endothelin in cirrhosis. Gastroenterology 104:1485-1491
171. Spiegel HU, Uhlmann D, Scommotau S, Giersch B, Sulkowski U (1996) Effect of the endothelin receptor antagonist bosentan on postischemic oxygen supply of the liver. J Invest Surg 9:439-445
172. Spiegel HU, Scommotau S, Uhlmann D, Giersch B (1996) Effect of the endothelin receptor antagonist bosentan on postischemic liver microcirculation. Zentralbl Chir 121:788-793
173. B-receptor antagonist (RO-47-0203) Transplant Proc 29:1365-1366
174. Pannen BH, Bauer M, Zhang JX, Robotham JL, Clemens MG (1996) A time-dependent balance between endothelins and nitric oxide regulating portal resistance after endotoxin. Am J Physiol 271:H1953-H1961
175. Hocher B, Zart R, Diekmann F, et al (1996) Paracrine renal endothelin system in rats with liver cirrhosis. Br J Pharmacol 118:220-227
176. Hocher B, Zart R, Diekmann F, et al (1995) Protective effects of the mixed endothelin receptor antagonist bosentan in rats with CCL4-induced liver injury. J Cardiovasc Pharmacol 26:S130-S131
177. Rockey DC, Chung JJ (1996) Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 98:1381-1388
178. Lazaratos S, Nakahara A, Goto K, Fukutomi H (1995) Bosentan antagonizes the effects of endothelin-1 on rat gastric blood flow and mucosal integrity. Life Sci 56:L195-L200
179. Matsumaru K, Kashimura H, Hassan M, et al (1997) Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in the rat: role of endogenous endothelin-1. J Gastroenterol 32:164-170
180. Hogaboam CM, Muller MJ, Collins SM, Hunt RH (1996) An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis. Eur J Pharmacol 309:261-269